//Presentations for Investors as Opposed to Partners

Presentations for Investors as Opposed to Partners

November 9, 2017

Neil Berkley, MBA
West Coast Business Development & Transactions, GlaxoSmithKlein

Neil Berkley will also be offering Office Hours on the same day, November 9, from 9:00 – 12:00 PM.

About Neil Berkley
Neil Berkley joined GSK in 2014 as part of WWBD’s efforts to expand its presence in the Western half of North America. In this role, Neil supports BD Heads in search and evaluation of West Coast opportunities. In 2016, Neil also became part of the WWBD Transactions team which is responsible for negotiating and structuring deals. Before joining GSK, Neil was Head of Business Development at Cadence Pharmaceuticals, a commercial stage acute care company, where he was part of the team who successfully sold the company to Mallinckrodt for $1.3B in cash. Prior to Cadence Pharmaceuticals, Neil held various roles with a primary focus on business development at Mpex Pharmaceutical, an antibacterial company he co-founded in 2001. During his time at Mpex, Neil helped raise over $100M in venture capital financing and closed multiple business development transactions including an option deal with GSK and the acquisition of Mpex by Aptalis in 2011. Neil also co-founded another San Diego-based biotechnology company, Vaxiion Therapeutics, which is developing a novel therapy for bladder cancer. Prior to his industry experience, Neil worked in several different academic laboratories studying immunology, cardiac virology and microbiology. Neil holds a BS in molecular biology from the University of California, San Diego and an MS in cellular and molecular biology as well as an MBA from San Diego State University.

2018-09-23T09:59:23+00:00November 9th, 2017|Events 2017|